Results 11 to 20 of about 14,810 (242)

A Prospective Crossover Clinical Trial of Esaxerenone and Eplerenone in Patients with Chronic Heart Failure Complicated by Hypertension [PDF]

Life
Esaxerenone, which blocks aldosterone binding, is approved to treat hypertension but not heart failure. We aimed to understand esaxerenone’s efficacy in treating chronic heart failure.
Akira Sezai, Msasnori Abe, Takashi Maruyama, Makoto Taoka, Hisakuni Sekino, Masashi Tanaka   +5 more
doaj   +4 more sources

Real-world practice patterns of eplerenone use for central serous chorioretinopathy [PDF]

International Journal of Retina and Vitreous, 2023
Purpose To report eplerenone use by retina specialists worldwide for central serous chorioretinopathy (CSCR). Methods A self-reporting questionnaire was distributed to retina specialists worldwide to gather clinicians’ perspectives on CSCR cases treated,
Ramesh Venkatesh, Vishma Prabhu, Aishwarya Joshi, Rubble Mangla, Rishi Singh, Lihteh Wu, Paolo Lanzetta, Baruch Kuppermann, Francesco Bandello, Francine Behar Cohen, Jay Chhablani   +10 more
doaj   +2 more sources

Short-term comparison between navigated subthreshold microsecond pulse laser and oral eplerenone for chronic central serous chorioretinopathy [PDF]

Scientific Reports, 2022
To compare the anatomical/functional changes after navigated subthreshold pulse laser (SML) and oral eplerenone therapy for chronic central serous chorioretinopathy (cCSC). A total of 36 eyes of 36 patients suffering from cCSC treated with navigated SML (
Lisa Toto, Rossella D’Aloisio, Chiara De Nicola, Federica Evangelista, Maria Ludovica Ruggeri, Luca Cerino, Maria Beatrice Simonelli, Agbéanda Aharrh-Gnama, Marta Di Nicola, Annamaria Porreca, Rodolfo Mastropasqua   +10 more
doaj   +2 more sources

The effectiveness of eplerenone in clinical practice from the standpoint of evidence-based medicine (twenty years on the guard of life)

Лечащий Врач, 2023
The article focuses on the negative role of hyperaldosteronism in cardiovascular diseases and the possibility of its control when using a selective mineralocorticoid receptor antagonist – eplerenone.
A. G. Evdokimova, R. I. Stryuk, V. V. Evdokimov, A. K. Kaptaeva   +3 more
doaj   +2 more sources

Ac-SDKP and eplerenone confer additive cardioprotection against angiotensin II-induced cardiac injury in C57BL/6J mice [PDF]

Journal of Molecular and Cellular Cardiology Plus
Eplerenone, a mineralocorticoid receptor antagonist, is an anti-hypertensive and cardioprotective drug. We showed that N-Acetyl-Seryl-Aspartyl-Proline (Ac-SDKP) exerts beneficial effects on the heart.
Suhail Hamid, Sarah Sarkar, Hongmei Peng, Khalid Matrougui, Pablo A. Ortiz, Jiang Xu, Tang-Dong Liao, Robert A. Knight, Nour-Eddine Rhaleb   +8 more
doaj   +2 more sources

Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms [PDF]

, 2014
Aim In the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF), aldosterone blockade with eplerenone decreased mortality and hospitalisation in patients with mild symptoms (New York Heart Association class II ...
Akehurst, R., Cowie, M.R., Krum, H., Lee, D., McMurray, J.J.V., Pitt, B., van Veldhuisen, D.J., Vincent, J., Wilson, K., Zannad, F.   +9 more
core   +5 more sources

Eplerenone ethanol solvate [PDF]

Acta Crystallographica Section E, 2008
Eplerenone [systematic name: 7α-(methoxycarbonyl)-3-oxo-9α,11-epoxy-17α-pregn-4-ene-21,17-carbolactone], an aldosterone receptor antagonist, crystallizes from ethanol as a monosolvate, C24H30O6·C2H6O.
Duan-Jun Xu, Jing-Jing Nie, Jian-Yong Yuan, Wei-Dong Ye, Qian Yang   +4 more
doaj   +3 more sources

Eplerenone attenuates pathological pulmonary vascular rather than right ventricular remodeling in pulmonary arterial hypertension [PDF]

, 2018
BACKGROUND: Aldosterone is a mineralocorticoid hormone critically involved in arterial blood pressure regulation. Although pharmacological aldosterone antagonism reduces mortality and morbidity among patients with severe left-sided heart failure, the ...
Arnold, N., Boehm, M., Braithwaite, A., Ghofrani, H.A., Grimminger, F., Kiely, D.G., Kojonazarov, B., Lawrie, A., Lu, C., Novoyatleva, T., Pickworth, J., Schermuly, R.T., Seeger, W., Weissmann, N.   +13 more
core   +3 more sources

Antihypertensive effect of the mineralocorticoid receptor antagonist eplerenone: a pooled analysis of patient-level data from comparative trials using regulatory-approved doses

Vascular Health and Risk Management, 2018
Mireille Fernet,1 Bruce Beckerman,2 Paula Abreu,2 Katharina Lins,3 John Vincent,2 Ellen Burgess4 1Department of Medical Affairs, Pfizer Canada Inc., Kirkland, QC, Canada; 2Department of Clinical Affairs, Pfizer Inc., New York, NY, USA; 3Department ...
Fernet M, Beckerman B, Abreu P, Lins K, Vincent J, Burgess E   +5 more
doaj   +3 more sources

Postpartum administration of eplerenone to mitigate vascular dysfunction in mice following a preeclampsia-like pregnancy [PDF]

Scientific Reports
Preeclampsia is a severe pregnancy complication associated with substantial injury to systemic vasculature, major organs, and the feto-placental unit, with an approximate mortality rate of 76,000 pregnant women and 500,000 babies each year.
Natalie K. Binder, Natasha de Alwis, Sally Beard, Bianca R. Fato, Anjali Garg, Lydia Baird, Morag J. Young, Natalie J. Hannan   +7 more
doaj   +2 more sources